User profiles for Keisuke Kamada
Keisuke KamadaThe Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association Verified email at jata.or.jp Cited by 611 |
[HTML][HTML] Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan
K Kamada, A Yoshida, S Iguchi, Y Arai, Y Uzawa… - Scientific reports, 2021 - nature.com
This study aimed to identify effective treatments against rapidly growing mycobacteria (RGM)
infections by investigating the minimum inhibitory concentrations (MIC) of 24 antimicrobial …
infections by investigating the minimum inhibitory concentrations (MIC) of 24 antimicrobial …
[HTML][HTML] Geographical distribution and regional differences in 532 clinical isolates of rapidly growing mycobacterial species in Japan
K Kamada, A Yoshida, S Iguchi, Y Arai, Y Uzawa… - Scientific reports, 2021 - nature.com
… This map was created by Keisuke Kamada at the following site (https://n.freemap.jp/). The
copyright of the completed map is held by Keisuke Kamada… Keisuke Kamada & Satoshi Konno …
copyright of the completed map is held by Keisuke Kamada… Keisuke Kamada & Satoshi Konno …
Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva
…, S Fujisawa, S Nakakubo, K Kamada… - Journal of …, 2020 - journalofinfection.com
In this journal, Azzi et al. reported that saliva was a reliable tool to detect SARS-CoV-2. 1
We prospectively compared the efficacy of PCR detection of SARS-CoV-2 between paired …
We prospectively compared the efficacy of PCR detection of SARS-CoV-2 between paired …
[HTML][HTML] Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification
…, S Oguri, K Taki, S Nakakubo, K Kamada… - International Journal of …, 2020 - Elsevier
Rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical
for the diagnosis of coronavirus disease 2019 (COVID-19) and preventing the spread of the …
for the diagnosis of coronavirus disease 2019 (COVID-19) and preventing the spread of the …
Associations of COVID-19 symptoms with omicron subvariants BA. 2 and BA. 5, host status, and clinical outcomes in Japan: a registry-based observational study
Background Previous SARS-CoV-2 infection and vaccination, coupled with the rapid evolution
of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We aimed to …
of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We aimed to …
[HTML][HTML] Comparative efficacy of tocilizumab and baricitinib administration in COVID-19 treatment: a retrospective cohort study
Y Kojima, S Nakakubo, N Takei, K Kamada… - Medicina, 2022 - mdpi.com
Background and Objectives: Tocilizumab and baricitinib have been observed to improve the
outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative …
outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative …
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia
…, J Nakamura, S Nakakubo, K Kamada… - Endocrine …, 2021 - jstage.jst.go.jp
We provide the details of the successful management of a patient with active Cushing’s
disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. The patient was a …
disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. The patient was a …
In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus
…, A Aono, T Asami, K Morimoto, K Kamada… - Antimicrobial agents …, 2023 - Am Soc Microbiol
The clinical importance of Mycobacterium abscessus species (MABS) infections has been
increasing. However, the standard treatment regimens recommended in the current …
increasing. However, the standard treatment regimens recommended in the current …
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID‐19: A retrospective study
Y Kojima, S Nakakubo, K Kamada… - Journal of Medical …, 2022 - Wiley Online Library
Immunomodulators (tocilizumab/baricitinib) improve outcomes of coronavirus disease 2019
(COVID‐19) patients, but the synergistic effect of remdesivir is unknown. The effect of …
(COVID‐19) patients, but the synergistic effect of remdesivir is unknown. The effect of …
Purulent lymphadenitis caused by Staphylococcus argenteus, representing the first Japanese case of Staphylococcus argenteus (multilocus sequence type 2250) …
…, T Kawai, I Kamimaki, R Mizushima, K Kamada… - Journal of infection and …, 2018 - Elsevier
Staphylococcus argenteus is a novel species separated from a strain of coagulase-positive,
non-pigmented S. aureus. Although S. argenteus has been reported to occur globally, …
non-pigmented S. aureus. Although S. argenteus has been reported to occur globally, …